Endobronchial Ultrasound Biopsy Market Forecast to Grow 7% Through 2030

The endobronchial ultrasound biopsy market is projected to rise from $0.66 billion in 2025 to $0.93 billion by 2030, driven by lung cancer demand, minimally invasive diagnostics and new imaging tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Endobronchial ultrasound biopsy is gaining traction because clinicians want more precise, minimally invasive ways to diagnose lung and mediastinal disease. - The market’s growth tracks with rising lung cancer cases, which increases demand for tissue sampling, staging and treatment planning tools. - The shift toward single-use devices and AI-assisted bronchoscopy could change procedure economics and access in outpatient settings.

What happened: - The Business Research Company published its Endobronchial Ultrasound Biopsy Global Market Report 2026 on July 2, 2026. - The report estimates the market grew from $0.66 billion in 2025 to $0.71 billion in 2026. - The report projects the market will reach $0.93 billion by 2030. - The forecast implies a 6.7% CAGR for 2026 and 7.0% CAGR through 2030. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region.

The details: - Endobronchial ultrasound biopsy uses a bronchoscope with an integrated ultrasound probe to visualize areas inside and around the airways. - The procedure helps clinicians collect tissue samples from lymph nodes or chest masses in real time. - The technique improves diagnostic accuracy for lung disease and mediastinal conditions. - The procedure can reduce the need for more invasive surgical biopsies. - Growth drivers in the report include rising lung cancer prevalence, wider use of minimally invasive diagnostics, expansion of hospital bronchoscopy facilities, ultrasound-guided biopsy improvements and greater awareness of early thoracic disease diagnosis. - Future growth drivers include demand for precise pulmonary diagnostic tools, growing use of single-use biopsy devices, AI-enhanced bronchoscopy imaging, higher investment in cancer diagnostics infrastructure and more outpatient biopsy procedures. - Cancer Research UK projected in March 2026 that the European age-standardized incidence of lung cancer in UK women will rise 2%, from 75.8 to 77.6 cases per 100,000 women annually between 2024-2026 and 2038-2040. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis, future trend analysis and updated graphics and tables. - The report offers a free sample. - The full report is available online.

Between the lines: - The forecast points to steady demand rather than a sudden market spike. - The strongest tailwinds are coming from clinical need, not just device innovation. - North America’s lead suggests mature adoption, while Asia-Pacific’s faster growth signals room for capacity expansion and new spending.

What's next: - The report expects broader use of AI-enabled imaging and single-use biopsy devices to support market growth through 2030. - Outpatient biopsy settings may become more common as providers look for faster and less invasive pulmonary diagnostics. - The market will likely keep expanding if lung cancer incidence and diagnostic screening continue to rise.

The bottom line: - Endobronchial ultrasound biopsy is moving from a niche diagnostic tool toward a larger global market, with lung cancer demand and technology upgrades driving the next phase of growth.